

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Analysis of the disproportionate metabolite data from the completed Phase 1 multi-ascending dose ("MAD") clinical trial revealed that PBI-4050 (fezagepras) primary metabolite was a glutamine conjugate.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Fezagepras
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Hematology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate
Details : Fezagepras is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperammonemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 27, 2022
Lead Product(s) : Fezagepras
Therapeutic Area : Hematology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Liminal BioSciences Provides an Update on Currently Planned Clinical Activities for Fezagepras
Details : Based on interim pharmacokinetic results from the ongoing fezagepras multiple ascending dose study, the Company has decided to stop its plans to move fezagepras into a Phase II clinical study in Idiopathic Pulmonary Fibrosis and a phase Ia/IIb study in H...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2021
Lead Product(s) : Fezagepras
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Healthy Volunteer Study of PBI-4050
Details : PBI-4050 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2021
Lead Product(s) : Fezagepras
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects
Details : PBI-4050 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 17, 2018
Lead Product(s) : Fezagepras
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Celerion
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome
Details : PBI-4050 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Alstrom Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 12, 2017
Lead Product(s) : Fezagepras
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PBI-4050 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 16, 2017
Lead Product(s) : Fezagepras
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance
Details : PBI4050 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cystic Fibrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2016
Lead Product(s) : Fezagepras
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PBI-4050 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Inflammatory Diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2016
Lead Product(s) : Fezagepras
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fezagepras
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PBI4050 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Diabetes Mellitus, Type 2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 29, 2015
Lead Product(s) : Fezagepras
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
